Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Biomaterials Access Assurance Act of 1998
Другие языки:

    Biomaterials Access Assurance Act of 1998

    Подписчиков: 0, рейтинг: 0
    Biomaterials Access Assurance Act of 1998
    Great Seal of the United States
    Long title An Act to establish rules governing product liability actions against raw materials and bulk component suppliers to medical device manufacturers, and for other purposes.
    Nicknames Biomaterials Access Assurance Act of 1997
    Enacted by the 105th United States Congress
    Effective August 13, 1998
    Citations
    Public law 105–230
    Statutes at Large 112 Stat. 1519
    Codification
    Titles amended 21 U.S.C.: Food and Drugs
    U.S.C. sections created 21 U.S.C. ch. 21 § 1601 et seq.
    Legislative history
    • Introduced in the House as H.R. 872 by George Gekas (RPA) on February 27, 1997
    • Committee consideration by House Judiciary, House Commerce
    • Passed the House on July 30, 1998 (Passed without objection)
    • Passed the Senate on July 30, 1998 (Passed unanimous consent)
    • Signed into law by President William J. Clinton on August 13, 1998

    Biomaterials Access Assurance Act of 1998 is a United States federal statute establishing liability exemptions for biomaterial suppliers selling chemical components and raw materials utilized in implantable devices for human recipients. The United States federal legislation sets forth rules limiting litigation costs or unwarranted lawsuits for biomaterial suppliers excluded from the design, production, and testing of implantable devices demonstrated as effective and safe to include adequate product warnings.

    The H.R. 872 bill was passed by the 105th United States Congressional session and enacted into law by the 42nd President of the United States Bill Clinton on August 13, 1998.

    Provision of the Act

    The 1998 Act was compiled as six sections establishing liability rulings for biomaterial elements sold by domestic and international suppliers to healthcare manufacturers located in the continental United States.

    21 U.S.C. § 1601 ~ U.S. Congressional findings
    21 U.S.C. § 1602 ~ Definitions
    21 U.S.C. § 1603 ~ General requirements, applicability, and preemption
    21 U.S.C. § 1604 ~ Liability of biomaterials suppliers
    21 U.S.C. § 1605 ~ Procedures for dismissal of civil actions against biomaterials suppliers
    21 U.S.C. § 1606 ~ Subsequent impleader of dismissed biomaterials supplier

    Legislation of 1995

    On January 31, 1995, the 104th United States House of Representatives and United States Senate introduced the initial liability exemption legislation for suppliers dealing in biomaterial bulk products.

    See also

    Biocompatibility
    Biomaterial Surface Modifications
    Biopolymer
    Mechanical properties of biomaterials
    Medical Device Regulation Act
    Surface modification of biomaterials with proteins

    External links


    Новое сообщение